# Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00051974** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 155 (—)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** VELCADE™ (bortezomib) for Injection (formerly PS-341)

## Key facts

- **NCT ID:** NCT00051974
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2004-09
- **Final completion:** —
- **Target enrollment:** 155 (—)
- **Last updated:** 2008-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051974, "Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00051974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*